Patient fitness is a better criterion for treatment than age in MM

Patient fitness is a better criterion for treatment than age in MM

VJHemOnc

1 year
75 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty, MD, PhD, of University Pierre & Marie Curie, France, speaking from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy, explains how, with the proper screening tests, elderly MM patients can tolerate and respond to treatment just as well as younger patients, and calls for improvements and refinements to the patient screening process to allow capable elderly patients to be treated.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 3 hours
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
0 Views
Cancer-News 1 day
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 1 day
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 1 day
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 1 day
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 1 day
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
2 Views
Massachusetts General Hospital 1 day